Hospital Based Health Technology Assessment: a tool for clinical management and sustainability.

Laura Sampietro-Colom, MD MScPH, PhD
Cristina Garcia-Fortea, MD MBA

Advancing Global Health & Health Care

2015 IHF CHICAGO
39th World Hospital Congress
Introduction: The dilemma for hospital decision-makers

Fixed budget + competing technologies
Introduction: How to make the best decision?

Hospital based Health Technology Assessment (HB-HTA)

- Doctors
- Companies
- National/International Documents (i.e. Health Technology Assessment)
Introduction: What does HB-HTA means?

Hospital-based Health Technology Assessment (HB-HTA) means performing HTA activities tailored to the **hospital context** for managerial decisions.

It includes the processes and methods used to produce HTA reports in and for hospitals.

*Definition developed by the partners of AdHopHTA*
Experience from two HB-HTA models

Hospital Clinic Provincial Barcelona

- High Tech University Hospital
- Beds: 600
- Professionals: 4,000 (600 physicians)
- Budget: € 460 million
- Organization: 9 Clinical Institutes + 2 Trans

Parc Sanitaria St Joan de Dèu General Hospital

- Community Hospital (teaching)
- Beds: 292
- Professionals: 800 (150 physicians)
- Budget: € 47 million
- Organization: standard
Experiences: HTA organization

Clinical Institute 1
Clinical Institute 2
Clinical Institute 3
Clinical Institute 4 … 9

HB-HTA Unit

PLUS Others

Doc (Surgeon)
Doc expert €
Doc research
Doc quality
Librarian
Nurse

Top Management
CEO, CMO

HB-HTA recommendation

HTA Committee
Experiences:
HTA Tools and Methods

Methods
- Review Scientific Evidence
- Analysis of Hospital Data
- Economic Evaluation:
  - Cost-effectiveness
  - Cost-Utility
  - Cost-minimization
  - Cost analysis
  - Budget Impact Analysis
- Qualitative research

Questions 1 - 3: Introduction
Questions 4 - 12: Technology
Questions 13 - 14: Patient
Questions 15 - 20: Organisation
Questions 21 - 26: Economy
Experiences:
Examples of Health Technologies Assessed

<table>
<thead>
<tr>
<th>Health Technology Assessed</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Capital Medical Equipment:</strong></td>
</tr>
<tr>
<td>• Robot Da Vinci (prostate)</td>
</tr>
<tr>
<td>• LIAC for IORT (breast cancer)</td>
</tr>
<tr>
<td><strong>Medium size Medical Devices:</strong></td>
</tr>
<tr>
<td>• Left ventricular assistive device (heart)</td>
</tr>
<tr>
<td>• Autologous platelet gel (TKR)</td>
</tr>
<tr>
<td><strong>Small size Medical devices:</strong></td>
</tr>
<tr>
<td>• Re-usable electrosurgical device for bipolar vessel sealing</td>
</tr>
<tr>
<td><strong>Diagnostic tests:</strong></td>
</tr>
<tr>
<td>• Point of Care Test for Flu diagnosis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Health Technology Assessed</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Botulinum Toxin (Dupuytrendisease)</td>
</tr>
<tr>
<td>• Sterilization bell (Pharmacy)</td>
</tr>
<tr>
<td>• VHIT (vertigo syndrome)</td>
</tr>
<tr>
<td>• Negative Pressure Wound Therapy</td>
</tr>
</tbody>
</table>
Experiences: HB-HTA Impact

Net Present Value (N=23 HTs):
- € 4 100 000 savings
- € 13 600 000 avoided waste

Satisfaction survey

- High Satisfaction Reported by Clinicians (informal communication)
Setting up International Standards: AdHopHTA

Body of Knowledge

Handbook

Networking HB-HTA

Toolkit

Database HB-HTA Reports

Adopting Hospital Based Health Technology Assessment
Setting up International Standards: AdHopHTA

7 Hospitals
- Hospital CLINIC de Barcelona (ES) - coordinator
- A. Gemelli University Hospital (IT)
- Odense University Hospital (DK)
- Centre Hospitalier Universitaire Vaudois (HE)
- Hospital District of Helsinki and Uusimaa (FI)
- Tartu University Hospital (EE)
- Ankara Numune Training and Research Hospital (TU)

2 HTA Agencies
- Ludwig Boltzmann Institute for HTA (AT)
- Norwegian Knowledge Centre for the Health Services (NO)

1 Business school
- IESE Business School (ES)

Participants 385 from 20 different countries
Setting up International Standards: AdHopHTA Handbook

Table of contents

Executive summary (first draft pending approval) ............................................... 7

CHAPTER 1 Introduction ................................................................. 15

1.1. Health Technology Assessment (HTA) .................................. 15

1.2. Hospital-based HTA (HB-HTA) ............................................. 15

1.3. Reasons for adopting HB-HTA ............................................. 17

1.4. Objectives of the handbook ................................................... 21

1.5. Target audience ................................................................. 22

CHAPTER 2 Current status of the management of health technologies in hospitals and the role of HB-HTA units therein .......................................................... 27

2.1. The process of adoption of health technologies in hospitals .... 28

2.2. The role of HB-HTA units in the process of adoption of health technologies in hospitals .................................................. 35

2.3. Organizational models of HB-HTA units .............................. 49

2.4. What information do decision-makers need when adopting new technologies? .................................................. 54

2.5. Types and quality of HB-HTA reports ................................... 60

2.6. Collaboration agreements between hospitals and national or regional HTA agencies .................................................. 97

2.7. Guiding principles for good practices in HB-HTA units – steps in development .................................................. 79

CHAPTER 3 Guiding principles for good practices in HB-HTA units .... 85

Dimension 1: The assessment process ....................................... 89

Dimension 2: Leadership, strategy and partnerships ................ 98

Dimension 3: Resources ............................................................. 109

Dimension 4: Impact ................................................................. 110

CHAPTER 4 Setting up an HB-HTA Strategy for the European Union .................................................. 115

4.1. Introduction ................................................................. 116

4.2. EU policy agenda for HTA .............................................. 119

4.3. An HB-HTA strategy for the EU ........................................ 119

4.4. Other recommendations .................................................. 121

Appendix 1: AdHopHTA mini-HTA template ................................ 126

Appendix 2: Process of development of the handbook ................. 132

Appendix 3: History of HB-HTA .................................................. 138

Acknowledgements ................................................................. 143

Glossary .................................................................................. 144

References .................................................................................. 148

www.adhophta.eu
Setting up International Standards: AdHopHTA Toolkit
Setting up International Standards: AdHopHTA Database

219 Entries
HB-HTA reports

<table>
<thead>
<tr>
<th>Title</th>
<th>Organisation</th>
<th>End of Project/HTA</th>
<th>Record Status</th>
<th>Type of Technology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug-eluting stents for peripheral artery disease</td>
<td>LBI-HTA</td>
<td>2014-07</td>
<td>Published</td>
<td>Therapeutic device</td>
</tr>
<tr>
<td>Observation unit for patients with COPD in non-invasive ventilation treatment</td>
<td>OUH</td>
<td>2014-12</td>
<td>In progress</td>
<td>Other</td>
</tr>
<tr>
<td>Percutaneous left atrial appendage (LAA) closure to prevent thromboembolic events in patients with atrial fibrillation</td>
<td>LBI-HTA</td>
<td>2014-07</td>
<td>Published</td>
<td>Therapeutic device</td>
</tr>
<tr>
<td>Exhaled nitric oxide (FENO) in the diagnosis and monitoring of treatment effect of asthma</td>
<td>HKM</td>
<td>2014-10</td>
<td>In progress</td>
<td>Diagnostic device</td>
</tr>
<tr>
<td>Implantation of endobronchial valves in patients with emphysema</td>
<td>LBI-HTA</td>
<td>2014-07</td>
<td>Published</td>
<td>Therapeutic device</td>
</tr>
<tr>
<td>Cytoreductive surgery Followed by hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis</td>
<td>LBI-HTA</td>
<td>2014-07</td>
<td>Published</td>
<td>Therapeutic device</td>
</tr>
<tr>
<td>Stereotactic and robotic-assisted radiofrequency ablation for liver carcinomas and colorectal liver metastases</td>
<td>LBI-HTA</td>
<td>2014-07</td>
<td>Published</td>
<td>Therapeutic device</td>
</tr>
<tr>
<td>OSNA</td>
<td>FCRI</td>
<td>2014-01</td>
<td>Published</td>
<td>Diagnostic device</td>
</tr>
<tr>
<td>Rapid-deployment aortic valve replacement</td>
<td>CHUV</td>
<td>2014-07</td>
<td>Published</td>
<td>Diagnostic device</td>
</tr>
<tr>
<td>Indocyanine green (ICG) lymphography in imaging diagnosis of secondary lymphedema</td>
<td>CHUV</td>
<td>2014-07</td>
<td>Published</td>
<td>Diagnostic device</td>
</tr>
<tr>
<td>Arthroscopic hip surgery</td>
<td>CHUV</td>
<td>2014-04</td>
<td>Published</td>
<td>Diagnostic device</td>
</tr>
</tbody>
</table>
4 Facts from Experience for Promoting HB-HTA in Hospitals

- HB-HTA separates the wheat from the chaff in new technologies based on scientific knowledge and hospital information
- HB-HTA allows you to make better informed investment decisions
- HB-HTA answer the questions relevant for an individual hospital’s HT decisions
- HB-HTA underpins better investment decisions that improve quality of care and save money to hospitals
THANK YOU! / GRACIES!

lsampiet@clinic.ub.es

www.adhophta.eu